Buparlisib matching placebo

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Head and Neck Squamous Cell CarcinomaSquamous Non-small Cell Lung Cancer

Phase 1

Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

TerminatedNCT01911325

Novartis PharmaceuticalsSquamous Non-small Cell Lung Cancer

Start: 2013-10-31End: 2015-08-31Updated: 2018-08-14

Phase 2

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

TerminatedNCT01852292

Novartis PharmaceuticalsHead and Neck Squamous Cell Carcinoma

Start: 2013-10-01End: 2017-03-30Updated: 2018-07-24

Related Papers

Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study.

2025-01-141 citations

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

2017-01-26154 citations

BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2016-05-2014 citations

Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

Journal of Clinical Oncology2016-05-2012 citations

BERIL-1: Biomarker results from targeted sequencing of circulating tumor DNA (ctDNA) and archival tissue in a randomized phase II study of buparlisib (BKM120) or placebo plus paclitaxel in patients with head and neck squamous cell carcinoma (HNSCC).

Journal of Clinical Oncology2016-05-201 citations